New way to help asthma sufferers found (Thinkstock photos/Getty Images)
A new study has offered new hope to asthma sufferers by
identifying ways to reduce the factors that lead to an asthma attack.
A UCSF researcher and his colleagues believe they have found a way to
help asthma sufferers by impeding the two most significant biological responses
that lead to an asthma attack. Asthma, a respiratory disorder that causes shortness of breath, coughing and
chest discomfort, results from changes in the airways that lead to the lungs.
Researchers from UCSF, John Hopkins University and Duke University have demonstrated that a specific calcium-activated chloride channel holds
valuable clues to reducing two biological processes that contribute to the
severity of asthma. These channels regulate airway secretions and smooth muscle
contraction, the two major factors that lead to an asthma attack. "Maybe
if we could inhibit both of these processes by blocking this one channel, then
we could affect the two symptoms of asthma," said senior author Jason
Rock, PhD, assistant professor at the UCSF Department of Anatomy.
Normally humans have few mucus-producing cells but asthma sufferers have
an elevated number of these cells in the lining of the tubes that lead to the
lungs. Asthmatics also have an abnormal amount of smooth muscle surrounding the
airway tubes. Even the slightest stimulus can cause these to contract. "The
overabundance of mucus plugging the airways combined with hyper-contractility
of the smooth muscle - when the tubes get really small - make it difficult to
move air in or out. A lot of people equate that with breathing through a
straw," Rock said.
Rock and his colleagues focused on a calcium-activated chloride channel
called TMEM16A. This channel secretes chloride ions in response to rises in
intracellular calcium. It regulates a significant number of biological processes such as neuron
firing, gastrointestinal activity and the secretion of sweat and tears. The
researchers wanted to prove that the channel was present in asthma. They
studied human lung samples and looked for the mRNA (messenger RNA which carries
information from the DNA to the sites of protein synthesis),
and compared protein levels in asthmatic and non-asthmatic patients. "We
found that the level of this channel was increased in the mucus producing cells
of asthmatics compared to non-asthmatics. And we also validated this in several
models of asthma, including mouse models. That was step one," Rock said.
Step two consisted of a screen to identify chemicals that inhibit the
activity of TMEM16A. The authors identified three chemicals that inhibit the
channel. "We tested the ability of these chemicals to inhibit TMEM16A and
other channels, and we found that they specifically block TMEM16A. It is great
that we came across these molecules that were unknown previously since we can
now try to get into clinical trials to benefit patients," Rock noted.
Then, the researchers simulated asthma in a dish and blocked the channel
to observe whether it affected mucus production. "Mucus produced by these
cells wasn't secreted as efficiently. We also studied airway smooth muscles of
human patients who had given their organs to science, and we could see that
blocking TMEM16A inhibited their contraction response as well," Rock explained. Rock is in the pre-clinical phase to
test the safety and effectiveness of the blockers in animal studies. If that
goes well, Phase One of clinical trials can begin. A paper on the study has
been published in the Proceedings of the National Academy of Sciences (PNAS).
Source: Times of India
Please share
No comments:
Post a Comment